On episode 11 we sit down with Paul Meister, Partner at Novalis LifeSciences, lead investor of our $100m Series B. Paul shares his perspectives on the potential for cell and gene therapies and the importance of data in driving the industry forward. Paul has extensive experience across pharmaceutical, biotech and life sciences, leading the merger of Thermo Electron and Fisher Scientific before becoming chair of Thermo Fisher Scientific and, later, chair and CEO of Syneos Health. When he caught up with Jason, he explained why he decided to join us on our mission to enable widespread patient access to cell and gene therapies and what he’s most excited about for the future of our partnership.
Learn more about Paul Meister
Ori Biotech Ltd 2022 © All rights reserved. Oribiotech is registered in England and Wales. Company registration 09757696.
"*" indicates required fields
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |